Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Open access
Pender, Michael P., Csurhes, Peter A., Smith, Corey, Douglas, Nanette L., Neller, Michelle A., Matthews, Katherine K., Beagley, Leone, Rehan, Sweera, Crooks, Pauline, Hopkins, Tracey J., Blum, Stefan, Green, Kerryn A., Ioannides, Zara A., Swayne, Andrew, Aftab, Blake T., Hooper, Kaye D., Burrows, Scott R., Thompson, Kate M., Coulthard, Alan, Khanna, Rajiv · 2018 · JCI Insight

Abstract

BACKGROUND: Increasing evidence indicates a role for EBV in the pathogenesis of multiple sclerosis (MS). EBV-infected autoreactive B cells might accumulate in the CNS because of defective cytotoxic CD8+ T cell immunity. We sought to determine the feasibility and safety of treating progressive MS patients with autologous EBV-specific T cell therapy. METHODS: An open-label phase I trial was designed to treat 5 patients with secondary progressive MS and 5 patients with primary progressive MS with 4 escalating doses of in vitro-expanded autologous EBV-specific T cells targeting EBV nuclear antigen 1, latent membrane protein 1 (LMP1), and LMP2A. Following adoptive immunotherapy, we monitored the patients for safety and clinical responses. RESULTS: Of the 13 recruited participants, 10 received the full course of T cell therapy. There were no serious adverse events. Seven patients showed improvement, with 6 experiencing both symptomatic and objective neurological improvement, together with a reduction in fatigue, improved quality of life, and, in 3 patients, reduced intrathecal IgG production. All 6 patients receiving T cells with strong EBV reactivity showed clinical improvement, whereas only 1 of the 4 patients receiving T cells with weak EBV reactivity showed improvement (P = 0.033, Fisher's exact test). CONCLUSION: EBV-specific adoptive T cell therapy was well tolerated. Clinical improvement following treatment was associated with the potency of EBV-specific reactivity of the administered T cells. Further clinical trials are warranted to determine the efficacy of EBV-specific T cell therapy in MS. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12615000422527. FUNDING: MS Queensland, MS Research Australia, Perpetual Trustee Company Ltd., and donations from private individuals who wish to remain anonymous.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.124714

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 159

Metadata

Authors
Pender, M. P., Csurhes, P. A., Smith, C., Douglas, N. L., Neller, M. A., Matthews, K. K., Beagley, L., Rehan, S., Crooks, P., Hopkins, T. J., Blum, S., Green, K. A., Ioannides, Z. A., Swayne, A., Aftab, B. T., Hooper, K. D., Burrows, S. R., Thompson, K. M., Coulthard, A., & Khanna, R.
Venue
JCI Insight
Published
2018-11-15
Volume
3
Issue
22
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2900501647
Cited by
159
References
2
FWCI
8.36
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis. https://app.cochat.ai/papers/10.1172/jci.insight.124714
The paper
Pender, M. P., Csurhes, P. A., Smith, C., Douglas, N. L., Neller, M. A., Matthews, K. K., Beagley, L., Rehan, S., Crooks, P., Hopkins, T. J., Blum, S., Green, K. A., Ioannides, Z. A., Swayne, A., Aftab, B. T., Hooper, K. D., Burrows, S. R., Thompson, K. M., Coulthard, A., & Khanna, R. (2018). Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis. JCI Insight. https://doi.org/10.1172/jci.insight.124714

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.